Wed, January 6, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Increased Target to $185 on, Jan 6th, 2021

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $175 to $185 on, Jan 6th, 2021.

Raghuram, nor any peers, have made any analyst calls on BTAI in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30